{
    "clinical_study": {
        "@rank": "122529", 
        "acronym": "TOPARP", 
        "arm_group": {
            "arm_group_label": "Olaparib", 
            "arm_group_type": "Experimental", 
            "description": "Oral Olaparib at a dose of 400mg twice daily, continuously on a 28 day cycle"
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, single arm, two part adaptive design phase II trial of Olaparib in\n      patients with advanced castration resistant prostate cancer.\n\n      The trial aims to evaluate the the anti-tumour activity of Olaparib in metastatic castration\n      resistant prostate cancer, identify molecular signatures of tumour cells in responding and\n      non-responding patients, and to identify predictive biomarkers of Olaparib response."
        }, 
        "brief_title": "TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Adenocarcinoma of the Prostate", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with advanced castration resistant prostate cancer will receive single agent\n      Olaparib at a dose of 400mg twice daily, continuously on a 28 day cycle.  Olaparib will be\n      administered until objective disease progression or unacceptable toxicity or patient\n      withdrawal for whatever reason"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject capable of understanding & complying with protocol requirements & signed the\n             informed consent form\n\n          2. Minimum age 18 years\n\n          3. Histologically confirmed adenocarcinoma of the prostate with tumour tissue available\n             for molecular analyses\n\n          4. At least one but no more than two previous taxane-based chemotherapy regimens. If\n             docetaxel chemotherapy is used more than once, this will be considered as one regime.\n             Patients may have had prior exposure to cabazitaxel treatment\n\n          5. At least 28 days since the completion of prior therapy, including major surgery,\n             chemotherapy & other investigational agents. Clinically relevant sequelae should have\n             resolved to grade 1 or less prior to recommencing treatment. For hormonal treatment &\n             radiotherapy refer to the protocol guidelines\n\n          6. Documented prostate cancer progression as described in the protocol.\n\n          7. Surgically or medically castrated, with testosterone levels of < 50 ng/dL (< 2.0 nM).\n             If the patient is being treated with LHRH agonists this must have been initiated at\n             least 4 weeks prior to Cycle 1 Day 1 & must be continued throughout the study.\n\n          8. Eastern Cooperative Oncology Group Performance Status of 0, 1, 2\n\n          9. Life expectancy > 12 weeks\n\n         10. Able to swallow a whole tablet\n\n         11. Patient & the patient's partner of childbearing potential, must agree to use\n             medically accepted methods of contraception during the course of the study & for 3\n             months after the last dose of study drug\n\n         12. Agreeable to have all the biomarker studies including the paired fresh tumour\n             biopsies.\n\n         13. CTC count of 5 cells/7.5mls blood or more at screening\n\n         14. Adequate bone marrow, hepatic & renal function as defined in the protocol\n\n        Exclusion Criteria:\n\n          1. Surgery, or local prostatic intervention (excluding a prostatic biopsy) less than 28\n             days of Cycle 1 Day 1\n\n          2. Less than 28 days from any active anticancer therapy or investigational agents. For\n             hormonal treatment & radiotherapy refer to the guidelines outlined in the inclusion\n             criteria\n\n          3. Prior treatment with a PARP inhibitor, platinum, cyclophosphamide or mitoxantrone\n             chemotherapy\n\n          4. Uncontrolled intercurrent illness including, but not limited to, active infection,\n             symptomatic congestive heart failure (New York Heart Association Class III or IV\n             heart disease), unstable angina pectoris, cardiac arrhythmia, uncontrolled\n             hypertension or psychiatric illness/social situations that would limit compliance\n             with study requirements\n\n          5. Any acute toxicities due to prior chemotherapy & / or radiotherapy that have not\n             resolved to a NCI-CTCAE v4.02 grade 0 or 1 with the exception of chemotherapy induced\n             alopecia & grade 2 peripheral neuropathy\n\n          6. Malignancy within the previous 2-years with a > 30% probability of recurrence within\n             12 months with the exception of non-melanoma skin cancer, in-situ or superficial\n             bladder cancer\n\n          7. Patients with myelodysplastic syndrome/acute myeloid leukaemia\n\n          8. Patients with known symptomatic brain metastasis are not suitable for enrollment.\n             Patients with asymptomatic, stable, treated brain metastases are eligible for study\n             entry\n\n          9. Patients with symptomatic or impending cord compression unless appropriately treated\n             beforehand & clinically stable & asymptomatic\n\n         10. Patients who have experienced a seizure or seizures within 6 months of study\n             treatment or who are currently being treated with cytochrome P450 enzyme inducing\n             anti-epileptic drugs for seizures\n\n         11. Patients receiving any of the following classes of inhibitors of CYP3A4 (see protocol\n             for guidelines & wash out periods)\n\n         12. Patients with gastrointestinal disorders likely to interfere with absorption of the\n             study medication\n\n         13. Initiating bisphosphonate therapy or adjusting bisphosphonate dose/regimen within 30\n             days prior to Cycle 1 Day 1.  Patients on a stable bisphosphonate regimen are\n             eligible & may continue\n\n         14. Presence of a condition or situation, which, may put the patient at significant risk,\n             confound the study results, or interfere significantly with participation in the\n             study"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "89", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01682772", 
            "org_study_id": "ICR-CTSU/2011/10030", 
            "secondary_id": [
                "2011-000601-49", 
                "CRUK/C12540/A12354", 
                "ISRCTN15124653", 
                "ISS22810018"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Olaparib", 
            "description": "Until objective disease progression, unacceptable toxicity or patient withdrawal for whatever reason", 
            "intervention_name": "Olaparib", 
            "intervention_type": "Drug", 
            "other_name": "AZD2281"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Olaparib", 
            "Adenocarcinoma", 
            "Prostate"
        ], 
        "lastchanged_date": "September 10, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sutton", 
                        "country": "United Kingdom", 
                        "state": "Surrey", 
                        "zip": "SM2 5PT"
                    }, 
                    "name": "Royal Marsden NHS Foundation Trust"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "NW1 2BU"
                    }, 
                    "name": "University College Hospital London"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer (TOPARP)", 
        "overall_contact": {
            "email": "toparp-icrctsu@icr.ac.uk", 
            "last_name": "TOPARP Trial Manager", 
            "phone": "020 8722 4156"
        }, 
        "overall_official": {
            "affiliation": "Institute of Cancer Research, United Kingdom", 
            "last_name": "Johann deBono", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Response will be defined on the basis of the following outcomes, if any of these occur patients will be considered to have responded:\nObjective response by modified RECIST\nPSA decline of \u226550% according to the Prostate Cancer Working Group 2\nConversion of circulating tumour cell count from \u22655 cells/7.5ml blood at baseline to <5 cells/7.5ml blood confirmed by at least two readings 4 weeks apart", 
            "measure": "Response rate to Olaparib", 
            "safety_issue": "No", 
            "time_frame": "Response will be evaluated 6 months post trial entry"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01682772"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "rPFS will be defined by either RECIST progression and/or progression on bone scan.  It will be measured from the date of trial entry to the first occurence of radiographic progression or death from any cause", 
                "measure": "Radiographic progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Radiographic progression free survival will be evaluated 6 months post trial entry"
            }, 
            {
                "description": "PFS will be measured from date of trial entry until radiographic progression, unequivocal clinical progression or death", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Progression free survival will be evaluated 6 months post trial entry"
            }, 
            {
                "description": "For patients who have achieved \u226550% decrease from the cycle 1 day 1 (baseline), the PSA progression date is defined as the date that a \u226525% increase and an absolute increase of \u22652ng.mL above the nadir is documented.  This must be confirmed by a second consecutive value.  For patients without a PSA decrease of this magnitude or no decrease at all, PSA progression date is defined as the date that a \u2265 25% increase and an absolute increase of \u2265 2 ng/mL above the baseline is documented. This must also be confirmed by a second consecutive value.", 
                "measure": "Time to PSA Progression", 
                "safety_issue": "No", 
                "time_frame": "Time to PSA progression will be evaluated 6 months post trial entry"
            }, 
            {
                "description": "Proportion of patients with conversion of CTC count from \u22655/7.5ml blood at baseline to <5/7.5ml blood nadir", 
                "measure": "CTC count conversion rate", 
                "safety_issue": "No", 
                "time_frame": "CTC count conversion rate will be evaluated 6 months post trial entry"
            }, 
            {
                "description": "Duration of PSA response is calculated from the time the PSA value first declines by at least 50% of the cycle 1 day 1 (baseline) value (must be confirmed by a second value) until the time there is an increase of 25% of PSA nadir, provided the absolute increase is at least 2 ng/mL. The increase must be confirmed by a second consecutive measurement.", 
                "measure": "Duration of PSA response", 
                "safety_issue": "No", 
                "time_frame": "Duration of PSA response will be evaluated 6 months post trial entry"
            }, 
            {
                "description": "The proportion of patients with grade 3/4 adverse events will be described along with other descriptive measures of safety and tolerability and evaluated by the IDMC", 
                "measure": "Number of participants with grade 3 or 4 adverse events as a measure of safety and tolerability.", 
                "safety_issue": "Yes", 
                "time_frame": "Will be evaluated 1) when the first 5 and 10 participants have completed the 1st cycle of treatment and, 2) at 6 months post trial entry."
            }, 
            {
                "description": "Time to radiographic progression (progression defined by either RECIST progression and /or progression on bone scan) will be measured from the date of trial entry to the first occurrence of radiographic progression.  Death from prostate cancer or any other cause without prior radiographic evidence of progression will not count as an event.", 
                "measure": "Time to radiographic progression", 
                "safety_issue": "No", 
                "time_frame": "Will be evaluated 6 months post trial entry"
            }, 
            {
                "description": "OS will be measured from the date of trial entry to the date of death (whatever the cause). Survival time of living patients will be censored on the last date a patient is known to be alive or lost to follow-up", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Will be evaluated 6 months post trial entry"
            }, 
            {
                "description": "PSA response and PSA progression are defined according to the consensus guidelines of the Prostate Cancer Clinical Trials Working Group 2.", 
                "measure": "PSA objective response", 
                "safety_issue": "No", 
                "time_frame": "Will be evaluated 6 months post trial entry"
            }
        ], 
        "source": "Institute of Cancer Research, United Kingdom", 
        "sponsors": {
            "collaborator": {
                "agency": "Royal Marsden NHS Foundation Trust", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Institute of Cancer Research, United Kingdom", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}